As amostras sangüíneas de 108 pacientes com diagnóstico clínico e laboratorial de Fibrose Cística foram analisadas com o objetivo de padronizar uma PCR clássica e uma PCR- ASO para a detecção da mutação delta F508. Dos 108 pacientes analisados, 23 eram homozigotos para a deleção delta F508 (21,29%), 50 eram heterozigotos (46,29%), e 35 não portadores (32,40%). Ambas as PCR apresentaram reprodutibilidade de 100%, e houve concordância absoluta entre os resultados deste estudo e aqueles dos laboratórios de referência. Concluímos que as padronizações propostas foram bem sucedidas, e recomendamos que os pacientes sejam testados com as duas técnicas, o que, encarece a investigação laboratorial, porém, aumenta significativamente o grau de confiabilidade dos resultados

Blood samples were drawn from 110 clinically and laboratory diagnosed Cystic Fibrosis patients in order to standardize one classical amplification and one ASO-PCR for detecting the delta F508 mutation. Twenty-four of 110 patients (21,8%) were homozygous for the delta F508 deletion, 51 were heterozygous, and the remaining 35 (31,8%) were non-carriers. Both PCR techniques presented with 100% reproducibility, and there were no discrepancies between our results and those from the reference laboratories. We concluded that the 2 amplification systems were successfully standardized in this study, and recommended that all patients should be tested by both techniques in order to increase reliability, albeit the increment of laboratory costs